Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
|Webcasts|July 13, 2021
Centralize, Track and Empower: Facilitating Good Clinical Data Review in Your Clinical Trial
Author(s)PerkinElmer, Inc.
Tuesday, July 13, 2021 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
Register Now:
Event Overview:
In response to ICH E6 R2 and the impending ICH E6 R3, most companies now heavily scrutinize their clinical trial data. And yet, despite heavy scrutiny, not all companies approach clinical trial data review with the same degree of rigor, even though how a company manages its data can significantly impact the success of its clinical trial.
Please join us for a live webinar to learn how clinical study teams can maintain good clinical data review by efficiently tracking the data review process, communicating its progress, and monitoring utilization to ensure safety and efficacy in a clinical trial.
Key Learning Objectives:
- Centralizing and expediting clinical data review process
- Tracking and collaborating on the data review status
- Reporting on data access and usage metrics
Who Should Attend:
People who attend the webcast should have the following job titles/keywords in their title:
- VP / Director of Clinical Development
- VP / Director of Biostatistics and Data Management
- Head of Clinical Safety / Drug Safety Officer
- VP/Dir of Development IT / R&D IT / Clinical IT
- Director/VP/Global Head Pharmacovigilance
- Director PV and Drug Safety
- VP & Head, Global PV & Epidemiology
- Director, Global PV DB Reporting & Analytics
Speakers
Brent Meyers
Vice President, Clinical & Translational Analytics
PerkinElmer Informatics
Meredith Nahm Zozus
Section Editor, Reviewer, Proofreader, Editor, Author
The Joe R. and Teresa Lozano Long School of Medicine, University of Texas Health Science Center San Antonio
Register Now:
Related to this article
In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
What Needs to Happen Beyond the Clinical Trial Modernization Act
3
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
4
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
5